Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients

• Main Authors: Karin Yaacoby-Bianu (Author), Zeev Schnapp (Author), Ilana Koren (Author), Anat Ilivitzki (Author), Mohamed Khatib (Author), Nadeem Shorbaji (Author), Michal Shteinberg (Author), Galit Livnat (Author)
• Format: Book
• Published: BMC, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Lumacaftor/Ivacaftor (LUM-IVA), a cystic fibrosis transmembrane conductance regulator (CFTR) protein corrector-potentiator combination, improves lung function and reduces pulmonary exacerbations (PEx) in F508del homozygous CF patients. However, the systemic effects of LUM-IVA out...